← Back

Yantai Dongcheng Pharmaceutical Co Ltd

Yantai Dongcheng Pharmaceutical Group Co., Ltd. operates in the raw materials, formulations, nuclear medicine, and big health sectors in China and internationally. It has four segments: API, Formulation, Radio Pharmaceutical, and Others. The company offers a range of products including powder injections, tablets, capsules, granules, and drop pills for various therapeutic areas, as well as active pharmaceutical ingredients such as heparin, chondroitin sulfate, hyaluronic acid, and glucosamine derivatives. It also provides nuclear medicine products like Technetium-labeled tracers and iodine seeds. Founded in 1998 and headquartered in Yantai, China, the company exports to approximately 40 countries and regions.

Price · split & dividend adjusted
News & notes moving 002675.CS
002675.CS▼

Dongcheng Pharmaceutical's 2026 interim net profit reaches 93.7401 million yuan

Dongcheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 93.7401 million yuan. The company's total operating revenue was 1.309 billion yuan, down 5.41% year-on-year; net cash inflow from operating activities was 62.2854 million yuan, down 76.72% year-on-year. The company's latest asset-liability ratio was 42.07%, gross margin was 53.06%, and diluted earnings per share was 0.11 yuan.
002675.CS ▼
Jiemian·28dRead more →
002675.CS▲3

Dongcheng Pharmaceutical's Shanxi Jinzhong Nuclear Medicine Production Center Obtains Radioactive Drug Production License

Andike, a subsidiary of Dongcheng Pharmaceutical, has officially obtained a radioactive drug production license for its nuclear medicine production center in Jinzhong City, Shanxi Province, and put it into operation. The center is located in the University Town Industrial Park of the Jinzhong Development Zone in the Shanxi Demonstration Zone. This approval marks the addition of a new nuclear medicine production center for Andike, meeting the requirements for production.
002675.CS ▲
Jiemian·35dRead more →
002675.CS▲2

Dongcheng Pharmaceutical's API Bemiparin Sodium Marketing Application Accepted

Dongcheng Pharmaceutical announced that the marketing application for its active pharmaceutical ingredient bemiparin sodium has been accepted by the National Medical Products Administration. Bemiparin sodium is an ultra-low-molecular-weight heparin obtained by depolymerization of porcine-derived heparin sodium, and it is currently marketed in more than 60 countries worldwide. Compared with other low-molecular-weight heparins, it has a smaller molecular weight and a higher anti-Xa to anti-IIa ratio. The corresponding finished product, bemiparin sodium injection, is indicated for preventing extracorporeal circuit clotting during hemodialysis, and for preventing thromboembolic disease in patients undergoing general surgery and orthopedic surgery.
002675.CS ▲
中国证券报·43dRead more →
002675.CS▲

Dongcheng Pharmaceutical Spends 100 Million Yuan on 7.4 Million Share Buyback

Dongcheng Pharmaceutical announced that as of July 31, 2026, the company had repurchased 7.4 million shares, accounting for 0.90% of total share capital, with a total repurchase amount of 100 million yuan. The highest transaction price was 15.27 yuan per share, and the lowest was 12.15 yuan per share. In the first quarter of 2026, the company achieved revenue of 626 million yuan and net profit attributable to the parent company of 33.44 million yuan.
002675.CS ▲
财中社·46dRead more →
002675.CS▲

Dongcheng Pharmaceutical's Heparin Sodium and Other APIs Receive GMP Certificates from Hamburg Health Authority

Dongcheng Pharmaceutical announced that it has recently received GMP certificates from the Hamburg health authority in Germany for its active pharmaceutical ingredients heparin sodium, enoxaparin sodium, nadroparin calcium, and chondroitin sulfate sodium, valid for three years. This certification signifies that these products can continue to be sold in the EU market, providing assurance for the company's overseas market expansion of APIs.
002675.CS ▲
CLS·50dRead more →
002675.CS▼

Dongcheng Pharmaceutical's Controlling Shareholder Pledges 19.41 Million Shares, Cumulative Pledge Exceeds 30% of Holdings

Dongcheng Pharmaceutical's controlling shareholder, Dongyi Biotech, has pledged 19.41 million shares, representing 15.54% of its holdings and 2.35% of the company's total share capital. As of the announcement date, Dongyi Biotech's cumulative pledged shares amount to 41.41 million, accounting for 33.16% of its holdings and 5.02% of the company's total share capital. In the first quarter of 2026, Dongcheng Pharmaceutical achieved revenue of 626 million yuan and a net profit attributable to the parent company of 33.44 million yuan.
002675.CS ▼
财中社·54dRead more →
© 2026 MarketDXAsset